Arbutus Biopharma - Stock Price History | ABUS

Historical daily share price chart and data for Arbutus Biopharma since 2021 adjusted for splits. The latest closing stock price for Arbutus Biopharma as of September 24, 2021 is 4.62.
  • The all-time high Arbutus Biopharma stock closing price was 12.35 on August 02, 2018.
  • The Arbutus Biopharma 52-week high stock price is 5.87, which is 27.1% above the current share price.
  • The Arbutus Biopharma 52-week low stock price is 2.43, which is 47.4% below the current share price.
  • The average Arbutus Biopharma stock price for the last 52 weeks is 3.43.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Arbutus Biopharma Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 2.7251 2.9400 6.2000 0.9101 3.5500 27.70%
2019 2.4173 4.0000 4.5700 0.8700 2.7800 -27.42%
2018 6.5330 5.4500 12.3500 3.5000 3.8300 -24.16%
2017 4.0934 2.5000 7.7000 2.5000 5.0500 106.12%
2016 3.6593 4.5200 5.3300 2.4500 2.4500 -44.94%
2015 6.3568 10.5000 10.5000 4.3400 4.4500 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.449B $0.007B
Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71